BiomX Inc. — Form 10-Q
Filed August 19, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 72/100
What the filing says
On May 21, 2026, BiomX assigned to Mandragola Ltd. a $3.3M warrant exercise receivable (from Pyu Pyu Capital warrant exercises at $1.00/share for 3.3M shares). In exchange, Mandragola satisfied BiomX's $3M convertible promissory note by offset. The remaining $300K excess is credited dollar-for-dollar against Mandragola's $2M line-of-credit commitment to BiomX. No cash changed hands; all transactions settled by assignment and offset.
Why this rating
Large relative to $11.9M market cap (~28% of value), but structured as non-cash receivables/payables swap. Eliminates debt obligation but creates contingent credit dependency; net effect unclear for a micro-cap.
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.